26U
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antih… Read more
26U (26U) - Total Liabilities
Latest total liabilities as of June 2025: €9.96 Million EUR
Based on the latest financial reports, 26U (26U) has total liabilities worth €9.96 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
26U - Total Liabilities Trend (2021–2024)
This chart illustrates how 26U's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
26U Competitors by Total Liabilities
The table below lists competitors of 26U ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TERADATA
BE:3T4
|
Germany | €1.53 Billion |
|
Lipigon Pharmaceuticals AB
ST:LPGO
|
Sweden | Skr2.99 Million |
|
ANGLO AMERICAN (NGLB.SG)
STU:NGLB
|
Germany | €34.93 Billion |
|
Ellen AB (publ)
ST:ELN
|
Sweden | Skr4.67 Million |
|
YELP-A
BE:Y9L
|
Germany | €240.67 Million |
|
Quintegra Solutions Limited
NSE:QUINTEGRA
|
India | ₹142.60 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down 26U's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 26U's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 26U (2021–2024)
The table below shows the annual total liabilities of 26U from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €9.94 Million | +2200.46% |
| 2023-12-31 | €432.00K | -94.08% |
| 2022-12-31 | €7.29 Million | +1260.63% |
| 2021-12-31 | €536.00K | -- |